ECULIZUMAB AND aHUS PATIENTS

That this House applauds the decision by the National Institute for Health and Care Excellence to recommend that the drug eculizumab be used for treating atypical haemolytic uraemic syndrome (aHUS); notes that this life-threatening disease affects around 200 people in England with 20 to 30 new patients diagnosed with the condition each year; and recognises that a petition of 30,000 signatures was presented to the House calling for the use of this drug.